TapImmune Inc. Stock Other OTC
Equities
US8760333091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
May. 15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
May. 15 | Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 30.95M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.71
x | P/E ratio 2025 * |
-2.71
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.8% |
Latest transcript on TapImmune Inc.
Managers | Title | Age | Since |
---|---|---|---|
Juan Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Norman Eansor
CHM | Chairman | 63 | 18-10-16 |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
1st Jan change | Capi. | |
---|---|---|
+49.34% | 56.95B | |
+39.98% | 40.26B | |
-6.97% | 39.32B | |
-4.42% | 28.37B | |
+11.83% | 26.45B | |
-17.93% | 19.41B | |
+29.43% | 12.54B | |
+25.24% | 12.21B | |
-0.40% | 12.15B |